Waiha Market - Rituximab Biosimilar Improving Cold Agglutinin...

добавлена новая статья Health

2026-07-20 07:12:37 -

Waiha Market - Rituximab Biosimilar Improving Cold Agglutinin Disease Access

Market Overview The Waiha market is broadening as rituximab biosimilar improves cold agglutinin disease access. The Waiha Market is projected to grow through 2030, driven by cold agglutinin disease recognition increase, complement pathway therapy emergence, rituximab biosimilar cost reduction, and secondary cold agglutinin syndrome management supporting expanded autoimmune hemolytic anemia...

0 Комментарии 0 Поделились 4 Просмотры 0 предпросмотр